“The study of cell-free DNA is a very active area of research, and we expect growth in applications such as analysis of liquid biopsies and cell-free fetal DNA,” said Herman Verrelst, Agilent vice president and general manager of the company’s Genomics Solutions Division and Clinical Applications Division. “With OneSight, researchers will be able to gain a deeper understanding of their sequencing data and apply that to a wide range of applications, from the early detection of cancer to screening for fetal abnormalities.”
The software platform is independent of NGS sequencing technology. With an established NGS infrastructure in place, OneSight allows labs to set up an end-to-end cfDNA analysis pipeline. According to the company, through the new platform’s visualization tools and statistical parameters, scientists can minimize the impact of recurrent technical variations and assess the presence of confounding biological factors such as segmental aberrations and genome-wide chromosomal instability.
The new software was developed with expertise from Cartagenia, a company Agilent acquired last year.